Sai Life Sciences Sustainability Report 2021

10 Track record of making it better 100+ clinical stage programs served; 25 active commercial programs and 10 in Phase III 39 programs advanced from IND to phase I, II or III USA, EU, Japan > 95% of products manufactured serve these highly regulated markets. USFDA, PMDA 100% successful track record of regulatory inspections across our R&D and manufacturing facilities. 17 of the top 25 big pharma companies as well as several small and medium biotechs utilize our services. Diverse therapy areas Oncology, CNS, Inflammation, Antivirals, Rare diseases and more PSCI Membership Sai Life Sciences became Associate Member of PSCI ACS – GCI Membership Sai Life Sciences became Associate Member of ACS-GCI ISO 14001 & 45001 Corporate office, R&D and Manufacturing facilities are IMS certified

RkJQdWJsaXNoZXIy MTIwMDc4NQ==